Salvia BioElectronics raises $60M Series B for closed-loop migraine abort implant commercialization
Summary
Salvia BioElectronics raised $60M in a Series B led by EQT Life Sciences, with Forbion and Gilde Healthcare, to complete clinical development and prepare commercial launch of their closed-loop cortical stimulation migraine implant. The device detects cortical spreading depolarization — the neural signature of migraine — and delivers preemptive stimulation before the attack becomes symptomatic. Total funding now exceeds $100M.
Why it matters
A $60M Series B for a migraine implant is a major statement about the commercial potential of closed-loop bioelectronic medicine beyond the established pain and movement disorder indications. Migraine affects 1 billion people globally and the refractory chronic migraine population of 3-4 million represents a massive unmet need with high willingness to pay for effective treatment.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial